Efficacy and Tolerability of Zolmitriptan Nasal Spray

Exclusion Criteria

• - Subject has history of basilar, ophthalmoplegic or hemiplegic migraine or serious neurologic condition associated with headache
• - Subject has used a MAOI within 2 weeks of randomisation or has been given SSRI therapy or migraine prophylactic agent within 3 months of randomisation. Subject requires treatment with propranolol or cimetidine or has had an intolerable or serious adverse event while using another triptan
• - Subject has a history or symptoms suggestive of ischemic heart disease, coronary artery vasospasm or other significant underlying cardiovascular disease or clinically significant abnormalities seen on an ECG or uncontrolled hypertension